8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 12, 2026·SEC
Jazz Pharmaceuticals plc(JAZZ)Earnings, Financials & Key Ratios
JAZZ•NASDAQ
Price updated Jun 19, 2026
AboutJazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.Show more
- Revenue$4.27B+4.9%
- EBITDA$766M-44.3%
- Net Income-$356M-163.6%
- EPS (Diluted)-5.84-167.5%
- Gross Margin88.21%-0.9%
- EBITDA Margin17.96%-46.9%
- Operating Margin5.26%-70.1%
- Net Margin-8.35%-160.6%
- ROE-8.47%-159.2%
JAZZ Key Insights
Jazz Pharmaceuticals plc (JAZZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 30.4% free cash flow margin
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Strong 5Y sales CAGR of 12.5%
- ✓Share count reduced 7.6% through buybacks
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when JAZZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
JAZZ Price & Volume
Jazz Pharmaceuticals plc (JAZZ) stock price & volume — 10-year historical chart
Loading chart...
JAZZ Growth Metrics
Jazz Pharmaceuticals plc (JAZZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12.41%
5 Years12.54%
3 Years5.26%
TTM9.2%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-93.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-98.53%
Return on Capital
10 Years7.31%
5 Years3.26%
3 Years4.98%
Last Year2.2%
JAZZ Recent Earnings
Jazz Pharmaceuticals plc (JAZZ) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$6.34+36.6%
$4.64
Rev
$1.1B+9.2%
$979M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$6.64+1.8%
$6.52
Rev
$1.2B+2.8%
$1.2B
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$8.13+36.6%
$5.95
Rev
$1.1B+1.3%
$1.1B
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$8.25-34.8%
$6.12
Rev
$1.0B-0.1%
$1.0B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $6.34vs $4.64+36.6% | $1.1Bvs $979M+9.2% |
| Q1 2026 | Feb 24, 2026 | $6.64vs $6.52+1.8% | $1.2Bvs $1.2B+2.8% |
| Q4 2025 | Nov 5, 2025 | $8.13vs $5.95+36.6% | $1.1Bvs $1.1B+1.3% |
| Q3 2025 | Aug 5, 2025 | $8.25vs $6.12-34.8% | $1.0Bvs $1.0B-0.1% |
Based on last 12 quarters of dataView full earnings history →
JAZZ Peer Comparison
Jazz Pharmaceuticals plc (JAZZ) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 AVNS | 1.17B | 24.94 | -17.08 | 1.95% | -9.69% | -8.91% | 0.17 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 | |
 INCY | 19.62B | 98.22 | 15.32 | 21.22% | 26.71% | 29.31% | 0.01 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 |
Compare JAZZ vs Peers
Jazz Pharmaceuticals plc (JAZZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
JAZZ Income Statement
Jazz Pharmaceuticals plc (JAZZ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.62B | 1.89B | 2.16B | 2.36B | 3.09B | 3.66B | 3.83B | 4.07B | 4.27B | 4.44B |
Revenue Growth % | 8.79% | 16.82% | 14.32% | 9.34% | 30.91% | 18.26% | 4.78% | 6.12% | 4.88% | 9.2% |
Cost of Goods Sold | 110.19M | 121.54M | 127.93M | 148.92M | 440.76M | 540.52M | 435.58M | 445.71M | 503.3M | 398.68M |
COGS % of Revenue | 6.81% | 6.43% | 5.92% | 6.3% | 14.24% | 14.77% | 11.36% | 10.95% | 11.79% | - |
Gross Profit | 1.51B▲ 0% | 1.77B▲ 17.3% | 2.03B▲ 14.9% | 2.21B▲ 8.9% | 2.65B▲ 19.8% | 3.12B▲ 17.5% | 3.4B▲ 9.0% | 3.62B▲ 6.6% | 3.76B▲ 3.9% | 2.97B▲ 0% |
Gross Margin % | 93.19% | 93.57% | 94.08% | 93.7% | 85.76% | 85.23% | 88.64% | 89.05% | 88.21% | 66.94% |
Gross Profit Growth % | 9.11% | 17.29% | 14.95% | 8.89% | 19.81% | 17.54% | 8.97% | 6.61% | 3.89% | - |
Operating Expenses | 979.66M | 1.15B | 1.5B | 1.84B | 2.48B | 3.18B | 2.82B | 2.91B | 3.54B | 3.42B |
OpEx % of Revenue | 60.52% | 61.06% | 69.46% | 77.7% | 80.25% | 87.02% | 73.55% | 71.43% | 82.95% | - |
Selling, General & Admin | 544.16M | 683.53M | 736.94M | 854.23M | 1.45B | 1.42B | 1.34B | 1.39B | 1.81B | 1.65B |
SG&A % of Revenue | 33.62% | 36.15% | 34.09% | 36.14% | 46.92% | 38.72% | 35.03% | 34.05% | 42.4% | - |
Research & Development | 198.44M | 226.62M | 299.73M | 335.38M | 505.75M | 590.45M | 849.66M | 884M | 782.74M | 736.18M |
R&D % of Revenue | 12.26% | 11.98% | 13.86% | 14.19% | 16.34% | 16.14% | 22.16% | 21.73% | 18.34% | - |
Other Operating Expenses | 237.06M | 244.39M | 464.79M | 646.97M | 525.77M | 1.18B | 627.28M | 637.31M | 947.86M | 2M |
Operating Income | 528.84M▲ 0% | 614.84M▲ 16.3% | 532.37M▼ 13.4% | 378.07M▼ 29.0% | 170.28M▼ 55.0% | -65.53M▼ 138.5% | 578.58M▲ 983.0% | 716.63M▲ 23.9% | 224.42M▼ 68.7% | 616.91M▲ 0% |
Operating Margin % | 32.67% | 32.52% | 24.63% | 16% | 5.5% | -1.79% | 15.09% | 17.61% | 5.26% | 13.9% |
Operating Income Growth % | -10.62% | 16.26% | -13.41% | -28.98% | -54.96% | -138.48% | 982.95% | 23.86% | -68.68% | - |
EBITDA | 694M | 831.57M | 902.53M | 656.33M | 722.76M | 563.94M | 1.22B | 1.38B | 766.42M | 994.04M |
EBITDA Margin % | 42.87% | 43.98% | 41.75% | 27.77% | 23.36% | 15.41% | 31.75% | 33.83% | 17.96% | 22.4% |
EBITDA Growth % | -1.62% | 19.82% | 8.53% | -27.28% | 10.12% | -21.97% | 115.85% | 13.1% | -44.33% | -20.86% |
D&A (Non-Cash Add-back) | 165.15M | 216.73M | 370.16M | 278.25M | 552.48M | 629.47M | 638.7M | 660.07M | 542M | 377.13M |
EBIT | 613.84M | 715.93M | 642.35M | 765.46M | 475.26M | 839.14M | 810.73M | 861.64M | -433.54M | -376.89M |
Net Interest Income | -77.76M | -78.5M | -72.26M | -99.71M | -278.77M | -288.24M | -289.44M | -238.1M | -195.05M | -141.34M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 77.76M | 78.5M | 72.26M | 99.71M | 278.77M | 288.24M | 289.44M | 238.1M | 195.05M | 101.44M |
Other Income/Expense | -88.73M | -87.58M | -82.16M | -105.94M | -283.83M | -317.18M | -283.66M | -247.94M | -853.01M | -835.95M |
Pretax Income | 440.11M▲ 0% | 527.26M▲ 19.8% | 450.21M▼ 14.6% | 272.13M▼ 39.6% | -113.55M▼ 141.7% | -382.7M▼ 237.0% | 294.92M▲ 177.1% | 468.69M▲ 58.9% | -628.59M▼ 234.1% | -219.04M▲ 0% |
Pretax Margin % | 27.19% | 27.88% | 20.83% | 11.51% | -3.67% | -10.46% | 7.69% | 11.52% | -14.73% | -4.93% |
Income Tax | -47.74M | 80.16M | -73.15M | 33.52M | 216.12M | -158.65M | -119.91M | -91.43M | -272.44M | -248.53M |
Effective Tax Rate % | -10.85% | 15.2% | -16.25% | 12.32% | -190.32% | 41.45% | -40.66% | -19.51% | 43.34% | 113.46% |
Net Income | 487.85M▲ 0% | 447.1M▼ 8.4% | 523.37M▲ 17.1% | 238.62M▼ 54.4% | -328.95M▼ 237.9% | -224.06M▲ 31.9% | 414.83M▲ 285.1% | 560.12M▲ 35.0% | -356.15M▼ 163.6% | 29.49M▲ 0% |
Net Margin % | 30.14% | 23.64% | 24.21% | 10.1% | -10.63% | -6.12% | 10.82% | 13.77% | -8.35% | 0.66% |
Net Income Growth % | 22.94% | -8.35% | 17.06% | -54.41% | -237.86% | 31.89% | 285.14% | 35.02% | -163.58% | -93.88% |
Net Income (Continuing) | 487.85M | 447.1M | 523.37M | 238.62M | -329.67M | -224.06M | 414.83M | 560.12M | -356.15M | 29.49M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 7.96▲ 0% | 7.30▼ 8.3% | 9.09▲ 24.5% | 4.22▼ 53.6% | -5.51▼ 230.6% | -3.58▲ 35.0% | 6.10▲ 270.4% | 8.65▲ 41.8% | -5.84▼ 167.5% | 0.45▲ 0% |
EPS Growth % | 24.18% | -8.29% | 24.52% | -53.58% | -230.57% | 35.03% | 270.39% | 41.8% | -167.51% | -98.53% |
EPS (Basic) | 8.13 | 7.45 | 9.22 | 4.28 | -5.51 | -3.58 | 6.55 | 9.06 | -5.84 | - |
Diluted Shares Outstanding | 61.32M | 61.22M | 57.55M | 56.52M | 59.69M | 62.54M | 72.07M | 66.01M | 60.98M | 66.1M |
Basic Shares Outstanding | 60.02M | 59.98M | 56.75M | 55.71M | 59.69M | 62.54M | 63.29M | 61.84M | 60.98M | 61.9M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
JAZZ Balance Sheet
Jazz Pharmaceuticals plc (JAZZ) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 968.28M | 1.23B | 1.63B | 2.84B | 2.61B | 2.61B | 3.44B | 4.63B | 4.17B | 4.58B |
Cash & Short-Term Investments | 601.03M | 824.62M | 1.08B | 2.13B | 591.45M | 881.48M | 1.63B | 2.99B | 2.44B | 1.84B |
Cash Only | 386.04M | 309.62M | 637.34M | 1.06B | 591.45M | 881.48M | 1.51B | 2.41B | 1.39B | 1.84B |
Short-Term Investments | 215M | 515M | 440M | 1.07B | 0 | 0 | 120M | 580M | 1.05B | 0 |
Accounts Receivable | 224.13M | 263.84M | 355.99M | 396.49M | 563.36M | 651.49M | 705.79M | 716.76M | 830.75M | 836.3M |
Days Sales Outstanding | 50.54 | 50.93 | 60.11 | 61.23 | 66.45 | 64.98 | 67.19 | 64.3 | 71.05 | 64.66 |
Inventory | 43.24M | 52.96M | 78.61M | 95.4M | 1.07B | 714.06M | 597.04M | 480.44M | 416.96M | 437.5M |
Days Inventory Outstanding | 143.25 | 159.03 | 224.28 | 233.82 | 888.34 | 482.19 | 500.3 | 393.44 | 302.39 | 421.73 |
Other Current Assets | 76.69M | 67.57M | 78.89M | 152.49M | 252.39M | 267.19M | 320.81M | 261.54M | 476.44M | 1.47B |
Total Non-Current Assets | 4.16B | 3.97B | 3.91B | 3.7B | 9.69B | 8.23B | 7.96B | 7.38B | 7.49B | 7.28B |
Property, Plant & Equipment | 170.08M | 200.36M | 270.89M | 257.1M | 343.42M | 301.38M | 234.99M | 227M | 258.74M | 258.9M |
Fixed Asset Turnover | 9.52x | 9.44x | 7.98x | 9.19x | 9.01x | 12.14x | 16.32x | 17.93x | 16.49x | 17.48x |
Goodwill | 947.54M | 927.63M | 920.02M | 958.3M | 1.83B | 1.69B | 1.75B | 1.72B | 1.83B | 1.8B |
Intangible Assets | 2.98B | 2.73B | 2.44B | 2.2B | 7.15B | 5.79B | 5.42B | 4.76B | 4.43B | 4.2B |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.33M | 0 | 8.6M |
Other Non-Current Assets | 24.09M | 52.28M | 55.34M | 30.96M | 52.84M | 64.39M | 73.94M | 119.64M | 106.58M | 101.8M |
Total Assets | 5.12B▲ 0% | 5.2B▲ 1.6% | 5.54B▲ 6.4% | 6.54B▲ 18.0% | 12.3B▲ 88.2% | 10.84B▼ 11.9% | 11.39B▲ 5.2% | 12.01B▲ 5.4% | 11.66B▼ 2.9% | 11.86B▲ 0% |
Asset Turnover | 0.32x | 0.36x | 0.39x | 0.36x | 0.25x | 0.34x | 0.34x | 0.34x | 0.37x | 0.39x |
Asset Growth % | 6.74% | 1.56% | 6.45% | 18% | 88.17% | -11.9% | 5.15% | 5.43% | -2.94% | -11.13% |
Total Current Liabilities | 293.95M | 345.49M | 364.49M | 653.75M | 809.3M | 933.19M | 1.54B | 1.04B | 2.24B | 2.25B |
Accounts Payable | 24.37M | 40.6M | 47.55M | 26.95M | 100.3M | 90.76M | 102.75M | 77.87M | 122.06M | 100M |
Days Payables Outstanding | 80.72 | 121.93 | 135.65 | 66.04 | 83.06 | 61.29 | 86.1 | 63.77 | 88.52 | 106.12 |
Short-Term Debt | 40.6M | 33.39M | 33.39M | 246.32M | 31M | 31M | 604.95M | 31M | 1.03B | 1.03B |
Deferred Revenue (Current) | 8.62M | 5.41M | 4.72M | 2.55M | 2.09M | 463K | 0 | 0 | 0 | 0 |
Other Current Liabilities | 63.99M | 62.51M | 85.03M | 124.59M | 193.1M | 169.41M | 142.32M | 189.76M | 1.02B | 1.12B |
Current Ratio | 3.29x | 3.57x | 4.47x | 4.34x | 3.23x | 2.79x | 2.24x | 4.46x | 1.86x | 2.04x |
Quick Ratio | 3.15x | 3.42x | 4.26x | 4.20x | 1.90x | 2.03x | 1.85x | 3.99x | 1.67x | 1.85x |
Cash Conversion Cycle | 113.07 | 88.03 | 148.73 | 229 | 871.73 | 485.89 | 481.39 | 393.97 | 284.92 | 380.27 |
Total Non-Current Liabilities | 2.12B | 2.1B | 2.06B | 2.22B | 7.52B | 6.82B | 6.12B | 6.88B | 5.1B | 5.08B |
Long-Term Debt | 1.54B | 1.56B | 1.57B | 1.85B | 6.02B | 5.69B | 5.11B | 6.08B | 4.33B | 47.3M |
Capital Lease Obligations | 0 | 0 | 151.23M | 140.03M | 87.2M | 71.84M | 59.23M | 38.94M | 50.89M | 159.43M |
Deferred Tax Liabilities | 383.47M | 309.1M | 224.09M | 130.4M | 1.3B | 944.34M | 847.71M | 676.74M | 594.47M | 2.45B |
Other Non-Current Liabilities | 176.61M | 218.88M | 109.37M | 101.15M | 117M | 106.81M | 104.75M | 86.61M | 124.52M | 4.49B |
Total Liabilities | 2.41B | 2.45B | 2.43B | 2.88B | 8.33B | 7.75B | 7.66B | 7.92B | 7.34B | 7.33B |
Total Debt | 1.58B | 1.6B | 1.77B | 2.25B | 6.15B | 5.81B | 5.79B | 6.16B | 5.42B | 1.08B |
Net Debt | 1.2B | 1.29B | 1.13B | 1.19B | 5.56B | 4.93B | 4.29B | 3.75B | 4.03B | -766.5M |
Debt / Equity | 0.58x | 0.58x | 0.57x | 0.61x | 1.55x | 1.88x | 1.55x | 1.51x | 1.26x | 0.24x |
Debt / EBITDA | 2.28x | 1.92x | 1.96x | 3.43x | 8.51x | 10.31x | 4.76x | 4.48x | 7.08x | 1.08x |
Net Debt / EBITDA | 1.72x | 1.55x | 1.26x | 1.82x | 7.69x | 8.74x | 3.52x | 2.72x | 5.26x | -0.77x |
Interest Coverage | 7.89x | 9.12x | 8.89x | 7.68x | 1.70x | 2.91x | 2.80x | 3.62x | -2.22x | -3.72x |
Total Equity | 2.71B▲ 0% | 2.76B▲ 1.6% | 3.11B▲ 12.8% | 3.66B▲ 17.6% | 3.97B▲ 8.3% | 3.09B▼ 22.2% | 3.74B▲ 21.1% | 4.09B▲ 9.5% | 4.32B▲ 5.5% | 4.53B▲ 0% |
Equity Growth % | 44.52% | 1.63% | 12.82% | 17.64% | 8.35% | -22.18% | 21.11% | 9.55% | 5.49% | 7.47% |
Book Value per Share | 44.25 | 45.04 | 54.06 | 64.75 | 66.43 | 49.34 | 51.86 | 62.02 | 70.81 | 68.57 |
Total Shareholders' Equity | 2.71B | 2.76B | 3.11B | 3.66B | 3.97B | 3.09B | 3.74B | 4.09B | 4.32B | 4.53B |
Common Stock | 61K | 61K | 61K | 61K | 61K | 61K | 61K | 61K | 6K | 0 |
Retained Earnings | 917.96M | 841.05M | 1.07B | 1.16B | 830.23M | 733.59M | 878.66M | 1.13B | 646.18M | 939.2M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -140.88M | -197.79M | -223.39M | -134.35M | -400.36M | -1.13B | -842.15M | -947.67M | -568.6M | -651M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JAZZ Cash Flow Statement
Jazz Pharmaceuticals plc (JAZZ) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 693.09M | 798.9M | 776.4M | 899.65M | 778.51M | 1.27B | 1.09B | 1.4B | 1.36B | 1.33B |
Operating CF Margin % | 42.82% | 42.25% | 35.92% | 38.06% | 25.16% | 34.76% | 28.48% | 34.31% | 31.77% | - |
Operating CF Growth % | 17.37% | 15.27% | -2.82% | 15.87% | -13.47% | 63.39% | -14.15% | 27.83% | -2.88% | -68.23% |
Net Income | 487.85M | 447.1M | 523.37M | 238.62M | -329.67M | -224.06M | 414.83M | 560.12M | -356.15M | 29.49M |
Depreciation & Amortization | 165.15M | 216.73M | 370.16M | 278.25M | 552.48M | 629.47M | 638.7M | 660.07M | 696.3M | 1.04B |
Stock-Based Compensation | 106.9M | 102.44M | 110.56M | 121M | 189.01M | 222M | 226.84M | 248.04M | 291.13M | 426.93M |
Deferred Taxes | -225.59M | -88.81M | -236.61M | -136.94M | 69.2M | -292.25M | -260.22M | -208.33M | -444.97M | -558.11M |
Other Non-Cash Items | 132.01M | 98.16M | 159.01M | 484.15M | 345.44M | 926.92M | 276.29M | 212.72M | 1.15B | 1.77B |
Working Capital Changes | 26.77M | 23.29M | -150.08M | -85.44M | -47.95M | 9.9M | -204.44M | -76.72M | 18.9M | -269M |
Change in Receivables | 12.28M | -40.13M | -92.33M | -38.65M | -92.73M | -90.14M | 0 | -21.11M | -106.28M | -158.13M |
Change in Inventory | -8.67M | -18.51M | -32.79M | -30.54M | -48.86M | -49.64M | 0 | -45.54M | -86.04M | -12.92M |
Change in Payables | 214K | 17.04M | 4.77M | -18.93M | 57.02M | -11.22M | 9.6M | -20.07M | 39.85M | -680K |
Cash from Investing | -268.95M | -394.49M | -155.3M | -1.01B | -5.21B | -446.23M | -163.06M | -508.19M | -1.51B | -1.22B |
Capital Expenditures | -113.95M | -131.47M | -182.34M | -379.25M | -27.64M | -498.19M | -23.96M | -38.07M | -58.75M | -118.57M |
CapEx % of Revenue | 7.04% | 6.95% | 8.43% | 16.05% | 0.89% | 13.61% | 0.63% | 0.94% | 1.38% | 2.67% |
Acquisitions | 85M | 111.1M | -142.2M | -364.25M | -6.23B | 53M | 0 | 0 | -858.05M | -1.72B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -85M | -63.2M | 101.33M | 378.51M | -17.89M | 0 | -19M | -10M | -1.95B | -1.22B |
Cash from Financing | -409.11M | -479.13M | -293.75M | 528.07M | 3.97B | -529.49M | -305.25M | 20.52M | -873.38M | -138.41M |
Debt Issued (Net) | -326.7M | -25.72M | -33.39M | 591.81M | 3.87B | -582.01M | -31M | 374.77M | -781M | -23.25M |
Equity Issued (Net) | -98.8M | -430.33M | -243.62M | -163.41M | 0 | 97.97M | -269.76M | -311.43M | -17.16M | -28.61M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -98.8M | -523.67M | -301.45M | -146.54M | 0 | -54K | -269.76M | -311.43M | -125.02M | -125.02M |
Other Financing | 16.39M | -23.08M | -16.74M | 99.68M | 99.66M | -45.44M | -4.49M | -42.82M | -75.22M | -86.56M |
Net Change in Cash | 20.07M▲ 0% | -76.41M▼ 480.7% | 327.72M▲ 528.9% | 420.43M▲ 28.3% | -466.32M▼ 210.9% | 290.03M▲ 162.2% | 624.83M▲ 115.4% | 906.55M▲ 45.1% | -1.02B▼ 212.6% | -97.65M▲ 0% |
Free Cash Flow | 579.14M▲ 0% | 667.43M▲ 15.2% | 594.07M▼ 11.0% | 520.39M▼ 12.4% | 732.98M▲ 40.9% | 773.78M▲ 5.6% | 1.07B▲ 38.0% | 1.35B▲ 26.2% | 1.3B▼ 3.8% | 1.25B▲ 0% |
FCF Margin % | 35.78% | 35.3% | 27.48% | 22.02% | 23.69% | 21.15% | 27.86% | 33.13% | 30.39% | 28.06% |
FCF Growth % | 41.61% | 15.25% | -10.99% | -12.4% | 40.85% | 5.57% | 38.03% | 26.2% | -3.77% | -16.31% |
FCF per Share | 9.44 | 10.90 | 10.32 | 9.21 | 12.28 | 12.37 | 14.82 | 20.42 | 21.27 | 18.84 |
FCF Conversion (FCF/Net Income) | 1.42x | 1.79x | 1.48x | 3.77x | -2.37x | -5.68x | 2.63x | 2.49x | -3.81x | 42.23x |
Interest Paid | 44.61M | 42.71M | 43M | 42.47M | 138.27M | 270.67M | 333.11M | 314.82M | 0 | 0 |
Taxes Paid | 174.12M | 164.22M | 183.61M | 226.82M | 271.22M | 94.68M | 177.88M | 114.91M | 0 | 0 |
JAZZ Key Ratios
Jazz Pharmaceuticals plc (JAZZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 21.25% | 16.35% | 17.84% | 7.05% | -8.63% | -6.36% | 12.16% | 14.31% | -8.47% | 0.71% |
Return on Invested Capital (ROIC) | 10.65% | 11.6% | 9.63% | 6.23% | 1.78% | -0.56% | 5.41% | 6.78% | 2.08% | 6.56% |
Gross Margin | 93.19% | 93.57% | 94.08% | 93.7% | 85.76% | 85.23% | 88.64% | 89.05% | 88.21% | 66.94% |
Net Margin | 30.14% | 23.64% | 24.21% | 10.1% | -10.63% | -6.12% | 10.82% | 13.77% | -8.35% | 0.66% |
Debt / Equity | 0.58x | 0.58x | 0.57x | 0.61x | 1.55x | 1.88x | 1.55x | 1.51x | 1.26x | 0.24x |
Interest Coverage | 7.89x | 9.12x | 8.89x | 7.68x | 1.70x | 2.91x | 2.80x | 3.62x | -2.22x | -3.72x |
FCF Conversion | 1.42x | 1.79x | 1.48x | 3.77x | -2.37x | -5.68x | 2.63x | 2.49x | -3.81x | 42.23x |
Revenue Growth | 8.79% | 16.82% | 14.32% | 9.34% | 30.91% | 18.26% | 4.78% | 6.12% | 4.88% | 9.2% |
Related:JAZZ Dividend History·JAZZ Revenue History·JAZZ Price History·JAZZ P/E History·JAZZ Financial Ratios·JAZZ Institutional Holders
JAZZ SEC Filings & Documents
Jazz Pharmaceuticals plc (JAZZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
JAZZ Frequently Asked Questions
Jazz Pharmaceuticals plc (JAZZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Jazz Pharmaceuticals plc (JAZZ) reported $4.44B in revenue for fiscal year 2025. This represents a 20601% increase from $21.4M in 2005.
Jazz Pharmaceuticals plc (JAZZ) grew revenue by 4.9% over the past year. Growth has been modest.
Yes, Jazz Pharmaceuticals plc (JAZZ) is profitable, generating $29.5M in net income for fiscal year 2025 (-8.3% net margin).
Dividend & Returns
Jazz Pharmaceuticals plc (JAZZ) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.
Jazz Pharmaceuticals plc (JAZZ) generated $1.25B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.